Results 121 to 130 of about 8,159 (145)

Combination therapy with spesolimab and apremilast for refractory generalized pustular psoriasis: a case report. [PDF]

Front Med (Lausanne)
Li Y, Li Z, Hu X, Cao T, Liu L.
europepmc   +1 more source

Generalized Pustular Psoriasis Confers Increased Risk of Pyoderma Gangrenosum: First Population-Based Evidence.

Dermatology
Ye H, Patel JD, Mohammad AP, Shiau C, Bae GH.   +4 more
europepmc   +1 more source

Distinct Mortality Risks in Generalized Pustular Psoriasis and Palmoplantar Pustulosis: A Nationwide, Population-Based, Cohort Study.

Dermatology
Jeon JJ, Lee S, Kim YS.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Trial of Spesolimab for Generalized Pustular Psoriasis

New England Journal of Medicine, 2021
Hervé Bachelez, Christian Thoma
exaly  

Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis

Journal of Allergy and Clinical Immunology, 2022
Patrick Baum, Sudha Visvanathan, Sandra Garcet   +2 more
exaly  

“Autoinflammatory psoriasis”—genetics and biology of pustular psoriasis

Cellular and Molecular Immunology, 2020
Ranjitha Uppala, Lam C Tsoi, Paul W Harms   +2 more
exaly  

Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options

Dermatology and Therapy, 2021
Alan Menter
exaly